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Current UK standard of care in frontline advanced stage (III or IV) symptomatic follicular 
lymphoma (FL) is immuno-chemotherapy with anti-CD20 monoclonal antibodies (mAbs) rituximab 
(R) or obinutuzumab (O), in combination with cyclophosphamide, vincristine and prednisolone 
(CVP) or cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), or bendamustine 
(B)1. Maintenance R or O are commonly offered to patients who achieved an objective response 
to induction1,2.
Patients currently receiving immuno-chemotherapy have a median OS of 15-20 years, with up to 
80% demonstrating an age and gender-matched OS compared to the general population3. To 
achieve a desirable patient treatment journey, key priorities are to optimise therapy responses 
whilst minimising treatment-related toxicities. 
GALLIUM reported increased toxicity with frontline O-based compared to R-based therapies, in 
particular: infusion reactions, neutropenia, neutropenic fever and infections1. The trial also 
demonstrated the effects of profound T-cell depletion associated with bendamustine therapy 
followed by anti-CD20 mAb maintenance, and reported a treatment-related mortality (TRM) of 
~5% in bendamustine-treated patients1,4. 
In light of these data, we performed a retrospective cohort study of consecutive newly diagnosed 
FL patients (2009-2019) treated within Oxford’s Tertiary Haematology Centre (UK), to assess 
efficacy outcomes and the 3-year infection morbidity/mortality following frontline therapy, and to 
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describing these outcomes in UK routine care, where patients can present with advanced age 
and/or co-morbidities, which often exclude patients from prospective clinical trials. Study 
methodology is further described in the supplementary text.  
Baseline patient, disease and treatment characteristics of 132 eligible patients are presented in 
Table 1. Median follow up of the whole cohort was 3 years (range: 0.08-3.00) for infections, 4.6 
years (range: 0.5-11.3) for OS and 4 years (range: 0.3-8.9) for PFS. The 3-year PFS and OS 
were 69.7% (Fig 1A) and 89% (Fig 1B), respectively. Patients receiving R-CVP had an inferior 3-
year PFS (Fig 1C) than other treatments (51.6% vs R-CHOP 79.8% vs BR 87.5% vs B-O 63.5%, 
p=0.001). R-CVP-treated patients also had an inferior 3-year OS (Fig 1D) (82.5% vs R-CHOP 
100% vs BR 90.6% vs B-O 87.5%, p=0.015). 
According to anti-CD20 mAb maintenance and across all patients, the 3-year PFS was 79.7% 
with maintenance compared to 52.9% without (p=0.001) (Fig 1E). There was a statistically 
significant 3-year OS difference in favour of maintenance use (97.4% vs. 75.1%, p=0.014) (Fig 
1F). 
Across the whole cohort, 74 patients experienced at least one infection (all grade) over a 3 year 
follow-up. Detailed infection-related outcomes are presented in Table 1S. There were a total of 
131 documented infections (G1-5): 76 during induction (R-CHOP: 26, R-CVP: 21, B-R or B-O: 22, 
2 each with hybrid BR/RCVP and hybrid RCVP/RCHOP, and 3 with R-GCVP). A total of 55 
infections occurred during maintenance (R: 52, O: 3). Across the whole cohort, 40 patients 
experienced a total of 62 infection-related admissions (G3-5) during induction (R-CHOP: 22, R-
CVP: 17, B-R or B-O: 16, hybrid BR/RCVP: 2, hybrid RCVP/RCHOP: 2, R-GCVP: 3), and 13 (of 
83 maintenance patients) experienced a total of 16 episodes of ≥G3 requiring admission at 
maintenance (R: 14, O:2).  
The regimen with the highest rate of patients experiencing any grade infection during the 3 year 
infection follow up was bendamustine-based (BR or BO) (63.4%: 26/41) which was comparable to 
R-CHOP (58.8%: 20/34), and the lowest was R-CVP (47.2%: 25/53) (p=0.200 for BR or BO vs. 
R-CVP). During maintenance, infection-related admissions were numerically higher in 
bendamustine-treated patients (22.6%:7/31) versus (R-CVP or R-CHOP: 16%: 8/50) (p=0.459).
Factors associated with an increased risk of all grade infections by UVA were having 
maintenance (odds ratio (OR): 2.09, p=0.05), and high CIRS-G (OR: 1.17, p=0.07). By MVA, 
compared to R-CVP, patients treated with BR (OR 3.77, p=0.02) and R-CHOP (OR 2.98, p=0.05) 
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Factors associated with an increased infective-related admissions by UVA included high CIRS-G 
(OR: 1.15, p=0.09). By MVA, significant factors were high CIRS-G (OR 1.34, p=0.05) and R-
CHOP compared to R-CVP (OR 3.18, p=0.03), Table 2S.
In this study, R-CVP resulted in lower OS and PFS rates than other induction comparators, which 
is in part driven by patient selection, but also known to provide an inferior PFS compared to other 
standard immuno-chemotherapy regimens5. The 3-year PFS improvement with maintenance mAb 
is consistent with PRIMA data (79.7% vs. 74.9%)2. Our 10-year OS rate in non-maintenance 
patients was significantly lower (40.9%) compared to 80% in the non-maintenance arm of 
PRIMA2, reflecting the nature of non-selective consecutive population-based data in patients with 
co-morbidities. Additionally, and in contrast with PRIMA, which showed no OS difference 
according to maintenance, our study demonstrated a significant OS advantage for maintenance, 
which likely reflects, at least in part, patient selection.
Despite the retrospective nature of our study, we have demonstrated the differences in infective 
morbidity according to the patient comorbidity status and immuno-chemotherapy choices which 
can inform decision making across different frontline FL therapeutic approaches. We show that B-
treated patients suffer from a high infective morbidity, as described in the follow up toxicity reports 
from GALLIUM1,4, and we demonstrated that infection-related hospitalisation was independently 
associated with R-CHOP and with a high baseline CIRS-G score.
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Table 1 title: 
Baseline patient, disease and treatment characteristics
Table 1 legend:
R-CVP (rituximab with cyclophosphamide, vincristine and prednisolone), R-CHOP (rituximab with 
doxorubicin, cyclophosphamide, vincristine and prednisolone), B-R (bendamustine with 
rituximab), B-O (bendamustine with obinutuzumab), CISR-G (Cumulative Illness Rating Scale for 
Geriatrics), COPD (chronic obstructive pulmonary disease), ECOG (Eastern Cooperative 
Oncology Group), Hb (haemoglobin), LDH (lactate dehydrogenase), FLIPI (follicular lymphoma 
international prognostic index), BM (bone marrow), PD (progressive disease). Number of patients 
with unknown data in the total cohort: a(1 ), b(1), c(2), d(2), e(52), f(2), g(1), h(2), i(33), j(1), k(58). 
*Four patients received other regimen: 1 hybrid BR/R-CVP, 2 hybrid R-CVP/R-CHOP and 1 R-
GCVP (rituximab with gemcitabine, cyclophosphamide, vincristine and prednisolone).
Figure 1 title: 
Kaplan Meier curves.
Figure 1 legend:
A: Progression-free survival (PFS) for all patients (3-year rate: 69.7% (95% confidence interval 
(CI): 60.6-77.1%)),  B: Overall survival (OS) for all patients (3-year rate: 89% (95% CI 82.1-
93.3%)), C: Progression-free survival (PFS) by regimen (3 year rate: RCVP  51.6% (95% CI 36.4-
64.9%) vs R-CHOP 79.8% (95% CI 60.4-90.4%) vs BR 87.5% (95% 70-95.1%) vs B-O 63.5% (CI 
23.8-86.6%) p=0.001), D: Overall survival (OS) by regimen (3 year rate: R-CVP 82.5% (95% CI 
69-90.5%) vs R-CHOP 100% vs BR 90.6% (95% 73.7-96.9%) vs B-O 87.5% (95% CI 38.7-
98.1%) p=0.015). RCVP vs. RCHOP vs. B-R vs. B-O), E: Progression-free survival (PFS) by anti-
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37.6-66%), p=0.001), F: Overall survival (OS) by anti-CD20 mAb maintenance (3 year rate: Yes 
97.4% (95% CI 89.9-99.3%) vs No: 75.1%, (95% CI 60.2-85%), p=0.014).
Table 1S title:
 Infection complications of frontline follicular lymphoma therapies over a 3 year follow-up
Table 1S legend:
 R-CVP (rituximab with cyclophosphamide, vincristine and prednisolone), R-CHOP (rituximab with 
doxorubicin, cyclophosphamide, vincristine and prednisolone), B-R (bendamustine with 
rituximab), B-O (bendamustine with obinutuzumab), Tx (treatment), GCSF (granulocyte colony 
stimulating factor), PCP (pneumocystis pneumonia), FU (follow up): IVIG (intravenous 
immunoglobulin). Number of patients with unknown data in the total cohort: 
a(52),b(2),c(4),d(4),e(4),f(5),g(2),h(1),i(45). *Four patients received other regimen: 1 hybrid BR/R-
CVP, 2 hybrid R-CVP/R-CHOP and 1 R-GCVP (rituximab with gemcitabine, cyclophosphamide, 
vincristine and prednisolone).
Table 2S title: 
Univariate and multivariate analyses of factors associated with increased overall incidence of 
infection and with increased infection-related admissions
Table 2S legend: 
CI (confidence interval), FLIPI (follicular lymphoma international prognostic index), CISR-G 
(Cumulative Illness Rating Scale for Geriatrics), COPD (chronic obstructive pulmonary disease), 
R-CVP (rituximab with cyclophosphamide, vincristine and prednisolone), R-CHOP (rituximab with 
doxorubicin, cyclophosphamide, vincristine and prednisolone), B-R (bendamustine with 











Table 1: Baseline patient, disease and treatment characteristics: R-CVP (rituximab with 
cyclophosphamide, vincristine and prednisolone), R-CHOP (rituximab with doxorubicin, cyclophosphamide, 
vincristine and prednisolone), B-R (bendamustine with rituximab), B-O (bendamustine with obinutuzumab), 
CISR-G (Cumulative Illness Rating Scale for Geriatrics), COPD (chronic obstructive pulmonary disease), ECOG 
(Eastern Cooperative Oncology Group), Hb (haemoglobin), LDH (lactate dehydrogenase), FLIPI (follicular 
lymphoma international prognostic index), BM (bone marrow), PD (progressive disease). Number of patients 






















(58). *Four patients 
received other regimen: 1 hybrid BR/R-CVP, 2 hybrid R-CVP/R-CHOP and 1 R-GCVP (rituximab with 





 (n= 53) 










Diagnosis to  treatment; 
median (range) in months  
1.1 (0.03-109.8) 2.4 (0.1-98.1) 1.6 (0.3-54.2) 1.3 (0.5-58.4) 1.6 (0.03 - 109.8) 
Age pre-Tx, median (range) 62 (33-78) 71 (33-90) 56 (28-83) 58(46-76) 63 (28-90) 
Sex (Male) 17/34 (50%) 26/53 (49%) 14/32 (43%) 3/9 (33%) 62/132 (47%) 
CIRS Severity index, mean 0.8 1.4 0.8 0.8 1.1 
Neutrophil count, median 
(range)a 
4.7 (1.7-13.1) 4.5 (1.0-12.3) 3.2 (0.3-12.7) 4 (1-5.3) 4.1 (0.3-13.1) 
Lymphocyte count, median 
(range)b 
1.2 (0.5-17.1) 1.44 (0.1-7.6) 1.4 (0.3-6.2) 1.3(0.35-25.5) 1.3 (0.1 - 25.5) 
Bronchiectasis historyc (Yes) 0/33 (0%) 0/52 (0%) 0/32 (0%) 1/9 (11%) 1/130 (1%) 
COPD historyd (Yes) 0/33 (0%) 5/52 (10%) 2/32 (6%) 0/9 (0%) 7/130 (5%) 
Smoking historye (Yes) 2/20 (10%) 5/30 (16%) 4/19 (21%) 0/7 (0%) 11/80 (14%) 
ECOG scoref                                                  0-1      
                                                 






Ann Arbor staging                   3-4 31/34 (91%) 45/53 (85%) 31/32 (97%) 9/9 (0%) 118/132(89%) 
Hb, median (range)g               <12 12/34. (35.3%) 9/52 (17.3%) 8/32. (25%) 3/9. (33.3%) 34/131 (26%) 
Raised LDH pre-Txh (Yes) 15/34 (44%) 15/51 (29%) 12/32 (37%) 4/9 (44%) 47/130 (36%) 
Number of nodal sites             >4         
   
23/34 (68%) 31/53 (58%) 27/32 (84%) 9/9 (100%) 91/132 (69%) 
FLIPI score                                 3-5 23/34 (68%) 29/53 (55%) 21/32 (66%) 8/9 (90%) 83/132 (63%) 
BM involvementi                        
Yes 
10/20 (50%) 21/40 (52%) 22/27(81%) 4/9 (44%) 58/99 (59%) 
Bulky disease (≥7cm)j             Yes 14/33 (42%) 11/53 (21%) 11/32 (34%) 2/9 (22%) 41/131 (31%) 
Raised β-2 microglobulink      Yes    
      








# of Rx cycles, median (range) 6 (4-8) 6 (1-12) 6 (2-7) 6 (5-6) 6 (1-12) 
Maintenance treatment        Yes 23/34 (68%) 27/53 (51%) 23/32 (72%) 8/9 (89%) 83/132 (63%) 
Number of maintenance cycles, 
median (range)* 




Yes 6 12 3 5 26 
No 14 14 20 2 52 
ongoing 3 1 0 1 5 




PD 0 6 2 3 11 
Toxicity 3 2 1 2 8 
Patient 
preference 
0 1 0 0 1 
Death 0 2 0 0 2 
Other 3 1 0 0 4 
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